ArticleCancer research and treatment2011

Phase II Study of S-1 Plus Either Irinotecan or Docetaxel for Non-small Cell Lung Cancer Patients Treated with More Than Three Lines of Treatment.

Dal Yong Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.